Pharming: 3 Key Takeaways for Long-Term Investors

Pharming’s third-quarter 2026 revenue rose 21% year over year to $117.6 million, while operating profit increased 89% to $29.9 million. RUCONEST revenue grew 14% to $93.8 million and Joenja sales rose 58% to $23.8 million; management also cited $190.9 million in cash and clinical expansion plans, including development of leniolisib for CVID, a market with 26 times APDS’s patient prevalence.

Analysis

The earnings signal is strongest as evidence of commercial leverage, not yet as proof of a durable growth multiple: flat operating expense alongside higher sales suggests incremental revenue may be converting efficiently, but one quarter cannot establish the run rate. Verify that profit conversion persists after channel-inventory movements and launch spending.

RUCONEST’s retention is the near-term defense, while oral HAE options—including BioCryst’s ORLADEYO and KalVista’s Ekterly—remain the structural substitution risk. Retention of high-volume users matters more than headline patient counts; a shift in those users could pressure revenue disproportionately. Joenja offers a more valuable growth option, but international expansion and pediatric approval do not by themselves prove repeatable uptake or favorable economics.

The CVID opportunity is the asymmetric 6–18 month catalyst, not current earnings support. Larger prevalence is not equivalent to an addressable market: efficacy, safety, patient identification, trial design, and eventual reimbursement remain gating factors. Cash reduces near-term financing/dilution risk, but does not de-risk clinical failure. Management’s channel-inventory caution also makes quarterly sales noisier than underlying demand. Near-term reaction may be positive; avoid extrapolating the quarter until volume, launch uptake, and clinical milestones corroborate it.

Key Decisions for Investors

• Favor a measured long PHAR on weakness rather than chasing an earnings-driven gap; size as a commercial-growth position with clinical-trial downside, and reassess after the next report of underlying RUCONEST volume and Joenja uptake.
• For a relative-value hedge, pair a small PHAR long with a short in a broader biotech or rare-disease basket rather than a direct HAE competitor: the thesis is company-specific execution, while a competitor short adds clinical and product-specific risks.
• Track three falsifiers: renewed decline in RUCONEST volume or high-volume patient retention; Joenja growth that stalls once launch/channel effects fade; or CVID data that fail to support clinically meaningful benefit. Any of these weakens the case for sustained earnings leverage.
• Treat CVID as optionality, not a base-case valuation input, until trial design, timing, and endpoints are clear. Revisit exposure around disclosed clinical milestones; the key missing evidence is whether the broader population responds consistently enough to support a registrable indication.